Hepatic MED1 disruption ameliorates obesity-related fatty liver by attenuating SREBP1-driven lipogenesis.
BACKGROUND & AIMS Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major global health concern, with obesity serving as a primary risk factor. Although Mediator subunit 1 (MED1) plays an important role in lipid metabolism, its specific contribution to obesity-related hepatic steatosis remains uncle...